| scholarly article | Q13442814 |
| P356 | DOI | 10.1093/NDT/GFP174 |
| P698 | PubMed publication ID | 19377055 |
| P50 | author | Angela Webster | Q37834876 |
| Jonathan Craig | Q38591193 | ||
| Germaine Wong | Q60227954 | ||
| Kirsten Howard | Q91325020 | ||
| Rachael Morton | Q43140522 | ||
| P2860 | cites work | Analysis and interpretation of cost data in dialysis: review of Western European literature | Q30625185 |
| End-stage renal disease and economic incentives: the International Study of Health Care Organization and Financing (ISHCOF). | Q36892279 | ||
| Immunosuppression use in renal transplantation from Asian transplant centers: a preliminary report from the Asian Transplant Registry | Q42169075 | ||
| Interpretation of cost-effectiveness analyses | Q42337459 | ||
| An economic and quality-of-life assessment of basiliximab vs antithymocyte globulin immunoprophylaxis in renal transplantation | Q43592410 | ||
| Cost evaluation of basiliximab treatment for renal transplant patients in Japan | Q44511821 | ||
| A randomized trial of thymoglobulin vs. alemtuzumab (with lower dose maintenance immunosuppression) vs. daclizumab in renal transplantation at 24 months of follow-up | Q46486529 | ||
| Health-related quality of life and estimates of utility in chronic kidney disease | Q46521735 | ||
| The role of value for money in public insurance coverage decisions for drugs in Australia: a retrospective analysis 1994-2004. | Q46955545 | ||
| International Study of Health Care Organization and Financing of renal services in England and Wales. | Q53232182 | ||
| P433 | issue | 7 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | immunosuppression | Q1455316 |
| P304 | page(s) | 2258-2269 | |
| P577 | publication date | 2009-04-17 | |
| P1433 | published in | Nephrology Dialysis Transplantation | Q15710302 |
| P1476 | title | The cost-effectiveness of induction immunosuppression in kidney transplantation | |
| P478 | volume | 24 |
| Q46448797 | A computer simulation model of the cost-effectiveness of routine Staphylococcus aureus screening and decolonization among lung and heart-lung transplant recipients |
| Q42969608 | Antibody induction therapy in adult kidney transplantation: A controversy continues |
| Q93354461 | Burden of cytomegalovirus reactivation post kidney transplant with antithymocyte globulin use in Thailand: A retrospective cohort study |
| Q38849979 | Comparative Effectiveness of Tacrolimus-Based Steroid Sparing versus Steroid Maintenance Regimens in Kidney Transplantation: Results from Discrete Event Simulation |
| Q58895301 | Cost Utility of Sirolimus versus Tacrolimus for the Primary Prevention of Graft Rejection in Renal Transplant Recipients in Mexico |
| Q37810962 | Cost-Effective Immunosuppressive Options for Solid Organ Transplantation: A Guide to Lower Cost for the Renal Transplant Recipient in the USA |
| Q39630797 | Cost-Effectiveness of Antibody-Based Induction Therapy in Deceased Donor Kidney Transplantation in the United States |
| Q37611806 | Cost-effectiveness of Medicare's coverage of immunosuppression medications for kidney transplant recipients |
| Q48610499 | Cost-effectiveness of screening type 2 diabetes patients for chronic kidney disease progression with the CKD273 urinary peptide classifier as compared to urinary albumin excretion. |
| Q49148148 | Economic evaluation of different treatment modalities in acute kidney injury |
| Q89909507 | Efficacy of anti-T-lymphocyte globulin-Fresenius as an induction agent in deceased-donor renal transplantation: A cohort study |
| Q38676864 | Estimating Health-State Utility Values in Kidney Transplant Recipients and Waiting-List Patients Using the EQ-5D-5L. |
| Q40704973 | Heterogeneity of induction therapy in Spain: changing patterns according to year, centre, indications and results |
| Q37591508 | Immunotherapy in elderly transplant recipients: a guide to clinically significant drug interactions |
| Q24240492 | Interleukin 2 receptor antagonists for kidney transplant recipients |
| Q41961410 | Outcomes of spousal versus related donor kidney transplants: A comparative study |
| Q86647086 | Polyclonal versus monoclonal induction therapy in a calcineurin inhibitor-free immunosuppressive therapy in renal transplantation: a comparison of efficacy and costs |
| Q38878030 | Use of ATG-Fresenius as an Induction Agent in Deceased-Donor Kidney Transplantation |
| Q84850063 | [Diagnosis-related groups for kidney transplantation] |
Search more.